NCT04833049View on ClinicalTrials.gov

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

June 20, 2021

Study Completion Date

June 20, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

TAK-994 Oral Tablet

TAK-994 tablet.

DRUG

[14C]TAK-994 Intravenous Infusion

\[14C\]TAK-994 intravenous infusion.

DRUG

[14C]TAK-994 Oral Suspension

\[14C\]TAK-994 oral suspension.

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04833049 - Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults | Biotech Hunter | Biotech Hunter